ABSTRACT
Ace Inhibitors
B
C
E
F
L
P
Q
R
T
Z
=
SKIN
Anaphylaxis
[1]
[1]
•
[1]
•
✓
Angioedema
[8]
[45] (15%)
[73]
[3]
[41] (70%)
[6]
[9]
[11]
[3]
[1]
✓✓
Bullous dermatitis
[1]
[1]
Bullous pemphigoid
[2]
[2]
Dermatitis
[3]
[1]
[1]
Diaphoresis
[1]
[1]
•
•
•
[3]
[2]
✓
DRESS syndrome
[2]
[1]
Edema
[1]
•
•
[4]
[1]
•
✓
Erythema
[1]
[1]
•
•
[1]
✓
Erythema multiforme
•
•
Erythroderma
[2]
[1]
[1]
Exanthems
[1]
[19] (10%)
[9]
[4]
[1]
[1]
✓
Exfoliative dermatitis
[4]
•
[2]
•
Facial edema
[1]
•
[1]
Jaundice
[1]
[1]
Kaposi’s sarcoma
[2]
[2]
[1]
Lichen planus pemphigoides
[2]
[3]
Lichenoid eruption
[12]
[2]
[2]
Linear IgA
[1]
[5]
Lupus erythematosus
[8]
[2]
[1]
Mycosis fungoides
[2]
[1]
Palmar–plantar pustulosis
[1]
[1]
Pemphigus
[1]
[23]
[10]
[1]
[1]
[1]
•
✓
Pemphigus foliaceus
[1]
[2]
[2]
[1]
[2]
[1]
[1]
[1]
[1]
✓
Peripheral edema
[3]
[2]
[1]
[3]
[3]
✓
Photosensitivity
•
[3]
[2]
•
•
[2]
[2]
✓
Pityriasis rosea
[6]
[2]
Pruritus
[1]
[8] (10%)
[3]
[1]
•
(<10%)
[7]
[3]
•
✓
Pseudolymphoma
[2]
[1]
[1]
Psoriasis
[8]
[3]
[1]
•
[1]
✓
Purpura
[1]
[1]
[2]
•
•
✓
Rash
[1]
[11] (4–7%)
[5]
[1]
[6]
[1] (<10%)
[5]
[4]
•
•
✓✓
Stevens–Johnson syndrome
[1]
•
[1]
Toxic epidermal necrolysis
[3]
•
Urticaria
[1]
[9] (7%)
[5]
•
[2]
•
•
✓
Vasculitis
[7]
[2]
[1]
•
[1]
✓
Xerosis
[1]
•
HAIR
Alopecia
[4]
[1]
[1]
•
(<10%)
✓
NAILS
Nail dystrophy
[2]
[1]
MUCOSAL
Burning mouth syndrome
[1]
[1]
[1]
Glossitis
[3]
•
Glossopyrosis
[1]
[1]
Oral burn
[1]
[1]
Oral ulceration
[4]
[2]
Sialorrhea
[1]
•
Tongue edema
[2]
[2]
[2]
Xerostomia
[1]
•
•
•
•
•
•
•
✓
B Benazepril; C Captopril; E Enalapril; F Fosinopril; L Lisinopril; P Perindopril; Q Quinapril; R Ramipril; T Trandolapril; Z Zofenopril These tables concentrate on skin, hair, nails and mucosal reactions.reaction noted (package inserts)
number of published reports of a reaction
(8%) highest incidence that has ever been noted or reported
? 20 reports or over or an incidence of 20% or over recorded for this reaction for a minority of drugs in the class
at least half the drugs in the class selection have this reaction noted or reported
all drugs in the class selection have this reaction noted or reported
Note: reactions noted or reported for only one drug in a class selection have been excluded AntiarrhythmicsA
Di
Dr
F
I
L
Pn
Pf
Pr
Q
S
=
SKIN
Acneform eruption
•
[2]
[2]
AGEP
[1]
[2]
Anaphylaxis
[2]
[1]
[7]
[1]
Angioedema
[2]
[3]
[1]
[1]
[2]
•
✓
Bullous dermatitis
[1]
[1]
Dermatitis
•
(5%)
[27]
[1] (6%)
[2]
[4]
✓
Diaphoresis
[2]
•
[1]
[1]
•
Eczema
(5%)
[3]
[2]
Edema
(<10%)
•
•
[2]
•
(5%)
✓
Erythema
(5%)
[3]
[1]
[1]
Erythema multiforme
[1]
[2]
[1]
[1]
Erythema nodosum
[2]
[1]
[1]
Exanthems
[5]
[1] (<5%)
[1]
[1]
[2]
[5] (8%)
[1]
[4]
[6] (17%)
✓
Exfoliative dermatitis
[1]
•
[2]
[1]
[5]
Fixed eruption
[1]
[2]
[1]
[2]
Hypersensitivity
[1]
[1]
[9]
[2]
[1]
Leukocytoclastic vasculitis
[1]
[1]
Lichen planus
[1]
[7]
Lichenoid eruption
[3]
[6]
[1]
Lupus erythematosus
[5] (5%)
[3]
[1]
[175] (15–20%)
[3]
[2]
[35]
✓
Necrosis
[1]
[3]
Photosensitivity
[41] (10–75%)
[1]
•
[1]
[1]
[21]
•
✓
Phototoxicity
[3]
[1]
[1]
[1]
Pigmentation
[68] (<10%)
[1]
[3]
?
Pruritus
[2] (<5%)
•
(5%)
•
[3]
•
•
[1]
[3]
(<10%)
✓
Psoriasis
[2]
[2]
[2]
[20]
[5]
[3]
✓
Purpura
[1]
[1]
[1]
[3]
•
[1]
[13]
✓
Rash
[1]
•
[7](5%)
•
•
•
•
[2](<10%)
(<10%)
•
✓
Raynaud’s phenomenon
[3] (59%)
•
Sjögren’s syndrome
[1]
[1]
Stevens–Johnson syndrome
•
[1]
[2]
Toxic epidermal necrolysis
[2]
[1]
[1]
[2]
Toxicity
[4]
[1]
[1]
[3]
[1]
Urticaria
[1]
•
[5]
[1] (<5%)
[1]
[3]
[1]
✓
Vasculitis
[5]
[5]
[5]
[1]
HAIR
Alopecia
[5]
•
•
[6]
[1]
•
✓
MUCOSA
Loral lesions
[1] (40%)
[1]
?
Oral mucosal eruption
[1]
[2]
Oral ulceration
[1]
[1]
[1]
Sialorrhea
(<10%)
[1]
Xerostomia
[2] (40%)
•
•
[1]
•
?
A Amiodarone; Di Disopyramide; Dr Dronedarone; F Flecainide; I Ibutilide; L Lidocaine; Pn Procainamide; Pf Propafenone; Pr Propranolol; Q Quinidine; S Sotalol Antibiotics, MacrolideA
C
E
=
SKIN
Anaphylaxis
[2]
[2]
[2]
✓✓
Angioedema
[1]
[1]
[1]
✓✓
Dermatitis
[1]
[4]
✓
Exanthems
[3]
[1]
[4] (<5%)
✓✓
Fixed eruption
[3]
[6]
✓
Hypersensitivity
[3]
[3]
[3] (<10%)
✓✓
Jarisch–Herxheimer reaction
[2]
[1]
✓
Pruritus
[3]
[1]
✓
Pustules
[1]
[1]
✓
Rash
[6] (2–10%)
[2]
[3]
✓✓
SDRIFE
[1]
[2]
✓
Stevens–Johnson syndrome
[6]
[1]
[7]
✓✓
Toxic epidermal necrolysis
[4]
[7]
✓
Toxicity
[1]
[1]
✓
Urticaria
[2]
[1]
[4]
✓✓
Vasculitis
[1]
[3]
[1]
✓✓
HAIR
Alopecia
[1]
[1]
✓
MUCOSAL
Gingival hyperplasia/hypertrophy
[1]
[1]
✓
A Azithromycin; C Clarithromycin; E Erythromycin AnticonvulsantsB
C
G
La
Le
O
Phb
Phy
Ti
To
V
Z
=
SKIN
Acne keloid
[1]
[2]
Acneform eruption
[1]
•
[1]
•
[1]
[8]
•
•
•
✓
AGEP
[5]
[1]
[1]
[5]
Angioedema
•
[5]
[1](<10%)
•
[2]
Anticonvulsant hypersensitivity syndrome
[19]
[2]
[17]
[1]
[10]
[10]
[6]
✓
Bullae
[1]
[1]
Bullous dermatitis
[4]
[1]
[5]
[1]
[1]
Bullous pemphigoid
[1]
[1]
Dermatitis
[7]
[1]
•
•
Diaphoresis
(<10%)
•
•
[1]
•
•
[1]
•
✓
DRESS syndrome
[46](77%)
[14](11%)
[7]
[6]
[12](6%)
[28](68%)
[7]
[3]
✓
Ecchymoses
•
•
•
(<6%)
[4](<5%)
•
✓
Eczema
[2]
•
•
•
•
Edema
[5]
[1]
•
[1]
•
•
[2]
•
✓
Epidermolysis bullosa
[1]
[1]
Erythema
[1]
[1](~10%)
[2]
Erythema multiforme
[16]
[4]
[2]
[7]
[11]
[3]
✓
Erythroderma
[12]
[1]
[2](16%)
[8](6%)
[3]
Exanthems
[35](17%)
[2]
[18](20%)
[1]
[4]
[13](70%)
[22](71%)
•
[1]
[3](14%)
•
✓
Exfoliative dermatitis
[24]
[1]
[6]
[15]
•
?
Facial edema
[2]
•
•
•
[1]
•
•
✓
Fixed eruption
[10]
[1]
[1]
[9]
[5]
[2]
[1]
✓
Furunculosis
•
(<5%)
Hand–foot syndrome
[1]
[1]
Hot flashes
[1]
(<10%)
•
(<10%)
Hyperhidrosis
[1]
•
Hypersensitivity
•
[69]
[1]
[28] (<10%)
[6]
[12]
[46] (23%)
[5]
[4]
✓
Lichen planus
[2]
[1]
Lichenoid eruption
[7]
[1]
Linear IgA
[1]
[8]
Lupus erythematosus
[35]
[4]
[2]
[19]
[5]
[1]
✓
Lymphadenopathy
[1]
•
•
•
Lymphoma
[2]
[6]
Lymphoproliferative disease
[5]
[1]
Mycosis fungoides
[3]
[1]
[1]
[7]
Oligohydrosis
[1]
[8]
Pemphigus
[3]
[1]
[2]
Peripheral edema
[1]
[11] (8%)
[1]
[1]
•
(<5%)
•
✓
Petechiae
[1]
•
•
[1](<5%)
•
Photosensitivity
[9]
[2]
[1]
[1]
•
•
[1]
✓
Pigmentation
[1]
[4]
•
•
Pruritus
[7]
[1]
[1]
[1]
[1]
[5]
•
[3]
[1]
[1] (2–6%)
✓
Pseudolymphoma
[17]
[1]
[1]
[31]
[2]
?
Psoriasis
[1]
[1]
•
Purpura
[8]
[1]
[1]
•
[2]
[4]
•
[2]
•
✓
Pustules
[5]
[1]
[3]
•
Rash
[29] (12%)
[2]
[49] (10–20%)
[4]
[10] (9%)
[4]
[12] (<10%)
[2] (5%)
[3] (6%)
[7] (10%)
[6] (7%)
✓
Scleroderma
[1]
[1]
Serum sickness
[1]
[2]
Sjögren’s syndrome
[1]
[1]
[1]
[1]
Stevens–Johnson syndrome
[95] (68%)
[2]
[45] (30%)
[3]
[7]
[20] (15%)
[56] (68%)
[10]
[3]
✓
Toxic epidermal necrolysis
[86] (68%)
[48] (13%)
[2]
[4]
[26] (13%)
[63] (68%)
[7]
[1]
✓
Toxicity
[2]
[1]
[1]
Toxicoderma
[1]
[1]
Urticaria
[14] (7%)
[1]
[2]
[1]
[5]
•
[1]
[1]
✓
Vasculitis
[7]
[1]
[1]
[1]
[11]
[3]
✓
Vesiculobullous eruption
•
•
Xerosis
•
•
[1]
[1]
HAIR
Alopecia
[7] (~6%)
[2]
[1]
[3]
•
[2]
[20] (<10%)
•
✓
Hirsutism
[1] (25%)
•
[8] (13%)
•
[2] (60%)
•
✓
Poliosis
[1]
[1]
NAILS
Nail changes
[2]
•
Nail hypoplasia
[1]
[2]
[3]
Nail pigmentation
[1]
[1]
MUCOSAL
Epistaxis
•
•
•
Gingival hyperplasia/hypertrophy
•
[3] (16%)
[56] (16–94%)
•
[1]
[7] (42%)
•
✓
Gingivitis
•
•
•
•
•
•
✓
Glossitis
•
(<5%)
•
Halitosis
•
[1]
Mucocutaneous eruption
[4]
[2]
Mucocutaneous lymph node syndrome
[2]
[1]
Oral ulceration
[2]
[1]
[1]
[1]
•
•
✓
Rectal hemorrhage
•
•
•
Sialorrhea
•
[1] (4–5%)
Stomatitis
•
•
•
(<5%)
•
Ulcerative stomatitis
•
•
Xerostomia
[1] (5%)
(6%)
•
[1]
[1]
[5] (16%)
[2] (<5%)
•
✓
B Brivaracetam; C Carbamazepine; G Gabapentin; La Lamotrigine; Le Levetiracetam; O Oxcarbazepine; Phb Phenobarbital; Phy Phenytoin; Ti Tiagabine; To Topiramate; V Valproic Acid; Z Zonisamide Antidepressants, TricyclicAmi
Amo
C
I
N
T
=
SKIN
Angioedema
[1]
[1]
Bullous dermatitis
[1]
[1]
Dermatitis
[1]
[1]
Diaphoresis
[1](<10%)
(<10%)
[2] (43%)
[8] (25%)
(<10%)
[1] (<10%)
✓✓
DRESS syndrome
[2]
[1]
Edema
[1]
(<10%)
•
[1]
✓
Exanthems
[2]
[6](6%)
•
•
✓
Fixed eruption
[1]
[1]
Hypersensitivity
[1]
[2]
Lichen planus
[1]
[1]
Lupus erythematosus
[1]
[1]
Photosensitivity
[3]
•
[3]
[3]
[2]
•
✓✓
Pigmentation
[4]
[1]
[13]
✓
Pruritus
[3]
[1]
[1] (6%)
[6]
✓
Purpura
[2]
•
[3]
✓
Rash
(<10%)
(8%)
Urticaria
•
[1]
[6]
✓
Vasculitis
[1]
[1]
[1]
✓
HAIR
Alopecia
[1]
•
•
[2]
•
•
✓✓
Alopecia areata
[1]
[1]
MUCOSAL
Stomatitis
[1]
[2]
Xerostomia
[15] (79%)
[1] (14%)
[6] (84%)
[16] (21%)
[9]
[2]
✓✓
Ami Amitriptyline; Amo Amoxapine; C Clomipramine; I Imipramine; N Nortriptyline; T Trimipramine Antihistamines (HI)Ce
Chl
Des
Dy
Fex
H
Lev
Lor
O
P
=
SKIN
AGEP
[1]
[1]
[1]
[3]
Anaphylaxis
[2]
[1]
[4]
[2]
•
[1]
✓
Angioedema
•
(<10%)
[1]
[3]
[1]
•
✓
Bullous dermatitis
•
•
Dermatitis
•
[4] (<10%)
[4]
[1]
[1]
•
[3]
✓
Desquamation
[1]
[1]
Diaphoresis
•
•
Eczema
[2]
[1]
Edema
•
•
Erythema multiforme
[2]
•
[2]
Exanthems
[1]
[1]
[3]
[1]
Fixed eruption
[6]
[4]
[3]
[3]
[3]
[1]
[1]
✓
Hypersensitivity
[1]
[1]
Palmar erythema
[1]
[1]
Photosensitivity
•
(<10%)
[3]
•
•
[12]
✓
Phototoxicity
•
[1]
[1]
[1]
Pruritus
[1]
[1]
[2]
[1]
Purpura
•
[1]
[1]
•
[2]
✓
Rash
•
•
•
[1]
[1]
✓
Toxic epidermal necrolysis
[3]
[2]
Toxicity
[2]
[1]
Urticaria
[8]
[1]
[3]
[3]
[1]
[4]
[3]
✓
Xerosis
•
•
HAIR
Alopecia
•
•
MUCOSAL
Oral ulceration
[1]
[1]
Sialorrhea
•
•
Stomatitis
•
•
Xerostomia
[2](6%)
(<10%)
[3]
[1](<10%)
[2](12%)
•
[9]
[2](<10%)
✓
Ce Cetirizine; Chl Chlorpheniramine; Des Desloratadine; Dy Diphenhydramine; Fex Fexofenadine; H Hydroxyzine; Lev Levocetirizine; Lor Loratadine; O Olopatadine; P Promethazine AntimalarialsAmo
A/L
Art
A/P
C
H
M
P
Quc
Qud
Qun
S
=
SKIN
Acneform eruption
[2]
[2]
AGEP
[1]
[1]
[22] (25%)
[1]
[2]
?
Anaphylaxis
[1]
[2]
•
Angioedema
[1]
[1]
•
[2]
•
•
[1]
✓
Bullous dermatitis
[2]
[2]
[1]
Dermatitis
[1]
[2]
[1]
•
[4]
[6]
✓
DRESS syndrome
[2]
[2]
[1]
Erythema
[2]
[1]
[1]
Erythema annulare centrifugum
[2]
[3]
Erythema multiforme
[2]
•
[1]
[4]
[1]
[2]
[3]
✓
Erythema nodosum
[1]
[1]
Erythroderma
[3]
[2]
Exanthems
[1]
[3] (<5%)
[4] (<5%)
[1] (30%)
[3]
[3] (80%)
[6] (17%)
[3] (<5%)
[1]
✓
Exfoliative dermatitis
[4]
[3]
[1]
[2]
[3] (8%)
[5]
[2]
[3]
✓
Fixed eruption
[1]
•
•
[3]
[3]
[2]
[12]
[2]
✓
Hypersensitivity
[1]
[1]
[1]
[1]
•
Lichen planus
[1]
[7]
[3]
Lichenoid eruption
[6]
[4]
[2]
[6] (12%)
[6]
[3]
✓
Livedo reticularis
[6]
[3]
Lupus erythematosus
[35]
[1]
?
Lymphoproliferative disease
[1]
[1]
[1]
Ochronosis
[2]
[1]
Pemphigus
[1]
[1]
Photosensitivity
[8]
[6]
[3]
[1]
[21]
[19]
[2]
✓
Phototoxicity
[1]
[1]
[3]
[1]
Pigmentation
[15]
[17](<10%)
[5]
[9]
[3]
[6]
✓
Pruritus
[3]
[2]
[3]
(<10%)
[36] (47%)
[12] (47%)
[2] (4–10%)
[2]
•
[3]
[1]
[2]
✓✓
Psoriasis
[18]
[12]
[2]
[1]
[5]
Purpura
[1]
[1]
[1]
[13]
[13]
[1]
✓
Pustules
[1]
[1]
[1]
[1]
[1]
Rash
[6] (11%)
[1]
[4] (<10%)
[1] (<10%)
•
[1]
(<10%)
[1]
•
✓
Stevens–Johnson syndrome
[1]
[4]
[1]
[2]
[25] (<10%)
[2]
[24] (<10%)
✓
Thrombocytopenic purpura
[2]
[8]
Toxic epidermal necrolysis
[5]
[3]
[2]
[15]
[2]
[3]
[17]
✓
Toxicity
[2]
[1]
Urticaria
[1]
[2]
[1]
[1]
[4]
[2]
[1]
[1]
[1]
[2]
•
✓
Vasculitis
[1]
[3]
[5]
[5]
HAIR
Alopecia
[1]
[1]
•
[2] (80%)
[1]
?
Hair pigmentation
[10]
[7] (<10%)
NAILS
Discoloration
[1]
[1]
Nail pigmentation
[2]
[3]
[2]
MUCOSAL
Aphthous stomatitis
[1]
[1]
[1]
[1]
Gingival pigmentation
[1]
[1]
Glossitis
•
•
Oral edema
[1]
[1]
[1]
Oral mucosal eruption
[2]
[1]
Oral pigmentation
[12]
[7]
[4]
[1]
Oral ulceration
[3] (6%)
[1]
[1]
Stomatitis
•
[2]
[1]
Amo Amodiaquine; A/L Artemether/Lumefantrine; Art Artesunate; A/P Atovaquone/Proguanil; C Chloroquine; H Hydroxychloroquine; M Mefloquine; P Pyrimethamine; Quc Quinacrine; Qud Quinidine; Qun Quinine; S Sulfadoxine BenzodiazepinesA
Cln
Clo
D
L
M
O
=
SKIN
Acneform eruption
[1]
[1]
Anaphylaxis
[1]
[1]
Angioedema
[1]
[1]
[1]
[1]
✓
Bullous dermatitis
[2]
[1]
Dermatitis
[5]
(<10%)
(<10%)
[3] (<10%)
(<10%)
(<10%)
✓
Diaphoresis
(16%)
[1]
•
•
•
•
✓
DRESS syndrome
[1]
[1]
Edema
(5%)
[2]
Erythema multiforme
[1]
[1]
[1]
Exanthems
[1]
[1]
[1]
[6]
✓
Exfoliative dermatitis
[1]
[2]
Fixed eruption
[2]
[1]
[1]
Peripheral edema
[1]
•
Photosensitivity
[4]
[1]
Pruritus
[2] (<10%)
[1]
[3]
Pseudolymphoma
[1]
[2]
[2]
Purpura
[1]
[4]
Rash
[4] (11%)
•
•
[2]
•
•
•
✓✓
Urticaria
[1]
[1]
[1]
Vasculitis
[1]
[1]
MUCOSAL
Sialopenia
(33%)
•
•
•
•
✓
Sialorrhea
•
(<10%)
(<10%)
[1]
•
(<10%)
✓
Xerostomia
[6] (15%)
[1]
•
•
•
•
✓
A Alprazolam; Cln Clonazepam; Clo Clorazepate; D Diazepam; L Lorazepam; M Midazolam; O Oxazepam Beta BlockersA
B
C
N
P
S
=
SKIN
Anaphylaxis
[2]
[1]
Cold extremities
[1]
[6] (36%)
?
Dermatitis
[1]
[1]
[2]
✓
Diaphoresis
•
[1]
Edema
[1]
(5%)
Fixed eruption
[1]
[1]
[1]
✓
Leukocytoclastic vasculitis
[1]
[1]
Lichenoid eruption
[1]
[1]
[3]
[1]
✓
Lupus erythematosus
[2]
[1]
[2]
✓
Necrosis
[3]
[3]
Peripheral edema
(<10%)
•
Photosensitivity
[1]
•
Pruritus
(<5%)
[1]
(<10%)
✓
Psoriasis
[7]
[1]
[20]
[3]
✓
Rash
[1]
(<10%)
•
[2] (<10%)
•
✓
Raynaud’s phenomenon
[2]
(<10%)
[3] (59%)
•
✓
Urticaria
[2]
[3]
Vasculitis
[1]
[1]
HAIR
Alopecia
[1]
[6]
•
✓
MUCOSAL
Xerostomia
•
[1]
•
✓
A Atenolol; B Bisoprolol; C Celiprolol; N Nebivolol; P Propranolol; S Sotalol BiologicsAld
Alm
Be
Bo
C
D
E
G
Ib
In
Ip
L
P
R
=
SKIN
Acne keloid
[1]
[1]
[2]
Acneform eruption
[5](10%)
[60] (92%)
[1] (<10%)
[26] (73–80%)
[32] (66–85%)
[2]
•
[1]
[17] (81%)
✓
AGEP
[1]
[1]
[1]
[6]
Anaphylaxis
•
[5](13%)
[1]
[1]
[1]
[7]
Angioedema
[2]
•
[1]
[3]
[1]
[4](11%)
Bullae
[1]
•
Bullous dermatitis
[1]
•
[1]
[4]
[1]
Bullous pemphigoid
[1]
[1]
Cellulitis
•
[1]
(5%)
[1]
Dermatitis
[2]
[1]
[1]
[4] (80%)
(<10%)
[2] (14%)
[1](6%)
[11] (12%)
[1]
[2]
✓
Dermatomyositis
[1]
[1]
Desquamation
[1]
[1] (8%)
[3] (89%)
[2] (39%)
[3] (13%)
?
Diaphoresis
(13%)
[1]
(8%)
[2](15%)
DRESS syndrome
[2]
[3]
[2]
Ecchymoses
[1] (16%)
[1](16%)
Eczema
[1]
(<10%)
[1]
[1]
[6](39%)
[2]
?
Edema
[3](47%)
[1](15%)
(23%)
[5](23%)
[1]
[33](80%)
[2](15%)
[1](10%)
[1](15%)
[1]
✓
Embolia cutis medicamentosa (Nicolau syndrome)
[1]
[1]
Erythema
[5](41%)
•
[2]
[3](14%)
[1]
(18%)
[1]
[5](<10%)
[2]
[1]
(5%)
[5](65%)
[1](16%)
✓
Erythema multiforme
[1]
[1](16%)
[1]
[1]
[1](16%)
Erythema nodosum
[3]
•
[1]
Erythroderma
[4]
[3]
Exanthems
[5]
[1]
[1](16%)
[5]
[3](8%)
[3](21%)
[8]
[3]
[5](20%)
[3](16%)
[1]
✓
Exfoliative dermatitis
[1](18%)
[1]
[3]
[1]
[2](25%)
?
Facial edema
•
[1]
[2](<10%)
[1]
Fissures
[4](14%)
[1]
[4](21%)
?
Folliculitis
[2]
[12](83%)
[9](11%)
[4]
[2]
[3]
?
Graft-versushost reaction
[1]
[1]
[1](14%)
[2](43%)
?
Granulomas
[1]
[1]
[3]
Hand–foot syndrome
[11](57%)
[5](6%)
[3](30–60%)
[2]
[3]
[1](10%)
[1]
[3](23%)
✓
Hematoma
•
[1]
[1]
Herpes simplex
[2](6%)
[2]
[2]
Herpes zoster
[3](9%)
[12](10–15%)
[6]
Hyperhidrosis
[1](8%)
(<10%)
[1]
[2](11%)
Hypersensitivity
[1](7%)
[8]
•
[1]
[1]
[5]
Kaposi’s sarcoma
[1]
[2]
[3]
Lesions
[1]
[1](8%)
Lichen planus
[5]
[8]
Linear IgA
[4]
[3]
Livedo reticularis
[1]
[2]
Lupus erythematosus
[1]
[1]
[1]
[1]
[17]
[1]
Malignancies
[1]
[6]
Necrolysis
[1]
[1]
Necrosis
[2]
[2]
[1]
[6]
[1]
Neutrophilic eccrine hidradenitis
[1]
[2]
Panniculitis
[3]
[2]
Papulopustular eruption
[6](83%)
[7](29%)
[3](21%)
[4](21–41%)
?
Pemphigus
[2]
[2]
[1]
Peripheral edema
(28%)
(13%)
[1](8%)
[5](83%)
[1](40%)
[3](44%)
•
[5](75%)
[3](83%)
[1](12%)
[1](14%)
✓
Petechiae
•
(<10%)
Photosensitivity
[1]
•
[1]
[1](<10%)
[2]
Pigmentation
[1]
[1](16%)
•
[1]
[9](60%)
[3](21%)
[2](16%)
[1]
✓
Pityriasis rubra pilaris
[1]
[1]
Pruritus
[7](24%)
(14–24%)
[1](91%)
[1](11%)
[9](40%)
[3](14%)
[8](21%)
[4](61%)
[3](10%)
[4](30%)
[17](47%)
[3](42%)
[9](91%)
[8](14%)
✓✓
Pseudo lymphoma
[1]
[3]
[1]
Psoriasis
[4]
[1]
[2]
[22]
[3]
?
Purpura
[1]
(8%)
[1]
[2]
[3]
[1]
[1]
[2]
[1]
[1]
✓
Pustules
[1]
[1]
[1]
Radiation recall dermatitis
[1]
[1]
[1]
[1]
Rash
[2](42%)
[5](13–40%)
[15](91%)
[9](67%)
[46](89%)
[9](34%)
[105](80%)
[59](66–85%)
[23](69%)
[5](11%)
[24](61%)
[15] (36%)
[28](91%)
[12](58%)
✓✓
Rosacea
[1]
[2]
[1]
[1]
Sarcoidosis
[1]
[47]
[2]
[1]
?
Scleroderma
[2]
[1]
Seborrheic dermatitis
[1]
[1]
[2]
Serum sickness
[1](8%)
[22](<17%)
?
Skin reactions
[1]
[1]
Squamous cell carcinoma
[1]
[1]
[2]
[1](7%)
Stevens–Johnson syndrome
[1]
[1]
[11]
[1]
[5]
[5]
Sweet’s syndrome
[1]
[7]
•
[1]
[1]
[3]
Telangiectasia
[1]
[1]
[1]
[1]
[1]
Thrombocytopenic purpura
[9]
[1]
[2]
Toxic epidermal necrolysis
[2]
[2]
[1]
[1]
[1]
[1]
[3]
✓
Toxicity
[6]
[9](16%)
[3](38%)
[18](63%)
[6](36%)
[7](84%)
[9](68%)
[8](30–44%)
[4]
[3](35%)
[6](75%)
[25](95%)
[2](12%)
✓
Transient acantholytic dermatosis
[1]
[1]
Tumor lysis syndrome
[2](17%)
[1](<5%)
[1]
[3](<5%)
Tumors
[5](11%)
[1](11%)
Ulcerations
[3]
[1]
[1]
•
[2]
[1]
Urticaria
[3]
[2](16–30%)
(<10%)
[1]
[1]
[3]
[2]
[1]
[5](8%)
✓
Vasculitis
[1]
[4]
[1]
[1]
[1]
[7]
[3]
✓
Vitiligo
[3]
[9]
[3]
Xerosis
(15%)
[1]
[1](16%)
[14](49%)
(<10%)
[11](56%)
[11](53%)
[1](<10%)
[1]
[2](16%)
[12](62%)
✓
HAIR
Abnormal hair growth
[2]
[1]
Alopecia
[2](10%)
[5](43%)
(5%)
[1](<10%)
[10](14%)
[6]
[1](10–15%)
[16](48%)
[1]
[3](54%)
[1]
✓
Hair changes
[3]
[3]
[2](9%)
Hair pigmentation
[2]
[3](18%)
Hirsutism
[1]
[1]
Hypertrichosis
[3]
[4]
[2]
[3]
NAILS
Nail changes
[1](21%)
[2](17%)
[1](17%)
[2](9–29%)
?
Nail disorder
[2]
•
Nail pigmentation
[1]
[1]
Paronychia
[1]
[14](14%)
[11](15%)
[13](14–32%)
[12](85%)
?
Pyogenic granuloma
[1]
[1]
[2]
[1]
MUCOSAL
Aphthous stomatitis
[1](5%)
[1]
[1]
[1]
[2]
[1]
Epistaxis
[5](17%)
[1]
[1](17%)
(15%)
[1]
Mucocutaneous eruption
[1]
[1]
Mucosal inflammation
[1]
[1](18%)
[1]
(6%)
Mucositis
[9](75%)
[2](45%)
[10]
[1](16%)
[9](21%)
[4](6–17%)
[2](15%)
[4](75%)
✓
Oral lichenoid eruption
[3]
[1]
Oral pigmentation
[3]
[1]
Oral ulceration
[1]
[2](18%)
[1]
[1]
[1]
[1]
[3](15%)
✓
Oropharyngeal pain
[1]
[1]
Perianal fistula
[1](67%)
[1]
?
Rectal hemorrhage
[1]
[1]
Stomatitis
[1](22%)
[1](14%)
[8](75%)
[1](43%)
[3](25%)
[1]
[9](9–19%)
[7](6–17%)
[1](30%)
[4](100%)
[2](69%)
✓
Xerostomia
[1]
(11%)
[1](33%)
[1](44%)
[4](41%)
(7%)
?
Ald Aldesleukin; Alm Alemtuzumab; Be Bevacizumab; Bo Bortezomib; C Cetuximab; D Dasatinib; E Erlotinib; G Gefitinib; I Imatinib; I Interferon Alfa; I Ipilimumab; L Lenalidomide; P Panitumumab; R Rituximab BisphosphonatesA
E
I
P
R
Z
=
SKIN
Angioedema
[2]
•
•
✓
Candidiasis
(6%)
(12%)
Eczema
[1](13%)
[1]
Edema
•
[3]
Exanthems
[1]
[1]
Hypersensitivity
[3](19%)
•
•
[1]
✓
Peripheral edema
[1]
(8%)
(5–21%)
✓
Pruritus
[1]
[1]
[1](4–5%)
•
✓
Rash
[5]
•
[1]
[1]
[1] (8%)
[3](6%)
✓✓
Stevens–Johnson syndrome
[1]
[1]
Toxic epidermal necrolysis
[1]
[1]
Urticaria
[1]
[1]
HAIR
Alopecia
[1]
[1](12%)
MUCOSAL
Stomatitis
[1]
•
(8%)
✓
A Alendronate; E Etidronate; I Ibandronate; P Pamidronate; R Risedronate; Z Zoledronate Calcium Channel BlockersA
D
F
I
Nic
Nif
Nis
V
=
SKIN
Acneform eruption
[1]
•
[1]
AGEP
[21]
[3]
?
Anaphylaxis
[1]
[1]
Angioedema
[6](6%)
[3]
[1]
[1]
[2]
[3]
✓
Dermatitis
(<10%)
[1]
[1]
Diaphoresis
•
[2]
[1]
•
[2]
•
[2]
✓
Ecchymoses
•
•
[1]
Eczema
[1]
[1]
Edema
[20](5–14%)
[4](<10%)
[1]
[6](7%)
•
[3]
[1]
[1]
✓✓
Erythema
[2]
•
[2]
Erythema multiforme
[2]
[11](31%)
[5]
[4]
✓
Erythema nodosum
[2]
[1]
Exanthems
[2]
[17](31%)
[2]
[2]
[9]
[1]
[8]
✓
Exfoliative dermatitis
[6]
[5]
•
[2]
✓
Facial edema
•
•
•
Hyperkeratosis
[1]
[2]
Hypersensitivity
[1]
[2]
Lichenoid eruption
[1]
[3]
Linear IgA
[1]
[1]
Lupus erythematosus
[5]
[3]
[2]
Peripheral edema
[44](34%)
[1](5–8%)
[6](22%)
[2](7%)
[12](6%)
[6](22%)
[1](<10%)
✓
Petechiae
[1]
•
•
Photosensitivity
[11]
[5]
[4]
Pigmentation
[2]
[10]
•
Pruritus
[3]
[6]
•
[1](6%)
[3]
•
[6]
✓
Pseudolymphoma
[1]
[1]
Purpura
[1]
[3]
[1]
[3]
[1]
✓
Pustules
[2]
•
Rash
(<10%)
[4]
•
•
[3]
[2]
•
[2]
✓✓
Stevens–Johnson syndrome
[1]
[4]
[3]
[5]
✓
Telangiectasia
[5]
[2]
[2]
Toxic epidermal necrolysis
[2]
[4]
[2]
Toxicity
[2]
[2]
[1]
Ulcerations
[1]
•
Urticaria
[1]
[5]
[1]
•
[3]
[7]
•
[5]
✓✓
Vasculitis
[2]
[6]
[4]
[2]
✓
Xerosis
•
•
HAIR
Alopecia
•
[2]
[4]
•
[5]
✓
Hair pigmentation
[1]
[1]
NAILS
Nail dystrophy
[1]
[1]
[1]
MUCOSAL
Gingival hyperplasia/hypertrophy
[28](31%)
[10](21%)
[5](2–10%)
[1]
[2]
[74](75%)
•
[10](19%)
✓✓
Oral ulceration
[1]
•
[1]
Xerostomia
[1]
[2]
[1]
•
•
•
•
•
✓✓
A Amlodipine; D Diltiazem; F Felodipine; I Isradipine; Nic Nicardipine; Nif Nifedipine; Nis Nisoldipine; V Verapamil CephalosporinsCdxl
Cclor
Ctan
Coxm
Cnir
Cixm
Ctxm
Czim
Caxn
Cpm
CF
Cple
=
SKIN
AGEP
[2]
[2]
[1]
[1]
[4]
[1]
✓
Anaphylaxis
•
[4]
[3]
[7]
[1]
[1]
[3]
[14]
•
✓
Angioedema
[1]
•
•
•
•
[3]
✓
Candidiasis
•
•
•
[3](5%)
•
Dermatitis
[1]
[2]
DRESS syndrome
[1]
[1]
[4]
[2]
Erythema
[1]
[1]
(9%)
Erythema multiforme
•
[6]
•
[1](13%)
[2]
[1]
[1]
✓
Exanthems
[1]
[9]
[2](6%)
•
[3]
[1]
[7](6%)
•
✓
Fixed eruption
[2]
[1]
[1]
Hypersensitivity
[1]
[4]
[1]
[2]
[1]
[4]
[2]
[2]
[1]
✓
Jarisch–Herxheimer reaction
[1]
[1]
Lupus erythematosus
[1]
[2]
Pemphigus
[1]
[1]
[1]
[1]
Pemphigus erythematodes
[1]
[2]
Pruritus
[1]
[4]
•
•
•
[1]
[3]
[3]
[2]
[3]
[7]
[1](9%)
✓✓
Pseudolymphoma
[1]
[1]
Pustules
[1]
[1]
Rash
•
[1]
[2]
[1]
•
[2]
[3]
[4]
[5]
[12](51%)
[7](10%)
[1]
✓✓
SDRIFE
[1]
[1]
Serum sickness
•
[31]
•
[2]
•
[1]
[2]
✓
Stevens–Johnson syndrome
•
[1]
•
•
•
[1]
[1]
•
[1]
[1]
✓
Toxic epidermal necrolysis
[1]
[2]
•
[1]
[1]
[1]
✓
Urticaria
[2]
[5]
•
[2]
•
[2](13%)
•
•
[4]
[1]
•
✓
MUCOSAL
Glossitis
[1]
[2]
Oral candidiasis
[1]
[1]
•
Oral mucosal eruption
[1]
[1]
Ist generation: Cdxl Cefadroxil; 2nd generation: Cclor Cefaclor, Ctan Cefotetan, Coxm Cefuroxime; 3rd generation: Cnir Cefdinir, Cixm Cefixime, Ctxm Cefotaxime, Czim Ceftazidime, Caxn Ceftriaxone; 4th generation: Cpm Cefepime; 5th generation: CF Ceftaroline Fosamil; Cple Ceftobiprole Disease-Modifying Antirheumatic Drugs (DMARDS)Ab
Ad
Az
Ce
Cy
E
G
H
I
M
P
R
S
=
SKIN
Abscess
[1]
[2]
[4]
[2]
Acneform eruption
[2]
[2]
[7](13%)
[1]
[6]
[1](67%)
?
AGEP
[2]
[1]
[22](25%)
[2]
[3]
?
Anaphylaxis
[1]
[1]
[8]
[2]
•
[1]
[10]
[9](<10%)
[7]
[4]
✓
Angioedema
[3]
[2]
•
[1]
[1]
•
[1]
[1]
[4](11%)
[2]
✓
Angioma
[1]
[1]
Atrophy
[1]
[1]
Basal cell carcinoma
[3]
[1]
[4]
[1]
[1]
[1]
Bullous dermatitis
[1]
[2]
[1]
[4]
[3]
[1]
Bullous pemphigoid
[1]
[1]
[6]
[3]
Burning
[1]
[1]
Candidiasis
[1]
[2](16%)
[4](5%)
[1]
[1]
Carcinoma
[2]
[3]
[2]
[2]
Cellulitis
[1]
[2](<5%)
[2]
[5]
[1]
[1]
Churg-Strauss syndrome
[1]
[1]
Cicatricial pemphigoid
[1]
[2]
Cyst
[5]
[1]
Dermatitis
[1]
[4]
•
[3]
[1]
[4]
[2]
[4]
[2]
[2]
✓
Dermatomyositis
[5]
[4]
[1]
[14]
Diaphoresis
[2](15%)
[1]
DRESS syndrome
[2]
[31](7%)
?
Ecchymoses
[1]
[1]
[1]
Eccrine squamous syringometaplasia
[1]
[1]
Eczema
[2](15%)
[2]
[5](19–30%)
[1]
?
Edema
[1](5–14%)
[3]
[2]
[1]
[1]
Erysipelas
[1]
(<5%)
Erythema
[1]
[1]
[1]
[1]
•
[1](16%)
Erythema annulare centrifugum
[3]
[1]
Erythema multiforme
[1]
[2]
[1]
[2]
[4]
(<5%)
[8]
✓
Erythema nodosum
[1]
[4]
[1]
[1]
[1]
[1]
[2]
✓
Erythroderma
[2]
[2]
[1]
Exanthems
[10](5%)
[1]
[2]
[4](<5%)
[4]
[5](15%)
[8]
[1]
[23](23%)
✓
Exfoliative dermatitis
[1]
[3]
[5]
Facial edema
[1]
[1]
[1]
[1]
[1]
[1]
[1]
✓
Fixed eruption
[1]
[1]
[1]
•
[1]
[7]
Folliculitis
[8]
[1]
[2]
[2]
Fungal dermatitis
[1](42%)
[1]
?
Furunculosis
[1]
[1]
[1]
Granuloma annulare
[1]
[1]
Granulomas
[1]
[2]
[1]
Granulomatous reaction
[5]
[5]
[1]
[1]
Henoch–Schönlein purpura
[2]
[3]
[1]
Herpes
[1]
[1]
Herpes simplex
[3](<5%)
[1]
[3](35%)
[4]
[1]
[4](10%)
[2]
[2]
✓
Herpes zoster
[3]
[9]
[8](27%)
[2]
[2]
[5]
[10]
[7]
[6]
✓
Hidradenitis
[2]
[1]
[2]
[1]
[1]
Hyperkeratosis
[1]
[1]
Hypersensitivity
[2]
[3]
[27]
•
[2]
[1]
[11](11%)
[2]
[3]
[5]
[16](<5%)
✓
Kaposi’s sarcoma
[1]
[14]
[5]
[1]
[3]
Keratoacanthoma
[1]
[1]
[1]
Leprosy
[1]
[2]
[1]
Leukocytoclastic vasculitis
[1]
[1]
[1]
Lichen planus
[2]
[1]
[2]
[4]
[3]
Lichenoid eruption
[5]
[1]
[1]
[3]
[4]
[3]
[7]
✓
Linear IgA
[2]
[1]
Lupus erythematosus
[16]
[1]
[25]
[3]
[33]
[43]
[1]
[34]
✓
Lupus syndrome
[3]
[2]
[2]
[11]
[1]
Lymphadenopathy
[1]
[1]
[1]
Lymphoma
[8]
[1]
[12]
[3]
[9]
[5]
[1]
✓
Lymphomatoid papulosis
[1]
[1]
Lymphoproliferative disease
[4]
[2]
[1]
[1]
[1]
[1]
Malignancies
[10](23%)
[3]
[1]
[2](8%)
[3]
[5]
[2]
[1]
✓
Melanoma
[6]
[1]
[2]
[1]
[1]
[1]
Molluscum contagiosum
[1]
[2]
[2]
Morphea
[1]
[1]
[2]
Necrosis
[4]
[1]
[1]
Necrotizing fasciitis
[1]
[1]
[1]
[1]
Neoplasms
[1]
[2]
[2]
[1]
[2]
[2]
[2]
[1]
✓
Neutrophilic dermatosis
[1]
[1]
[4](76%)
?
Nevi
[3]
[1]
[2]
Nodular eruption
[1]
[3]
[15]
Non-Hodgkin’s lymphoma
[1]
[1]
[2]
Palmar–plantar pustulosis
[3]
[1]
Pemphigus
[1]
[75]
[1]
?
Pemphigus foliaceus
[1]
[16]
Peripheral edema
[1]
(<5%)
[1]
[3](10%)
[1]
[1]
(<10%)
[1](14%)
✓
Photoallergic reaction
[1]
[1]
Photosensitivity
[1]
[6]
[9](5%)
[4](10%)
Phototoxicity
[3]
[1]
Pigmentation
[1](37%)
[17](<10%)
(<10%)
[3]
?
Pityriasis lichenoides chronica
[1]
[1]
[2]
Porokeratosis
[4]
[1]
[1]
Pruritus
•
[5]
[1]
[1]
[2](12%)
[2](14%)
[12](47%)
[8](20%)
[1](<5%)
[2](44–50%)
[8](14%)
[7](10%)
✓
Pseudolymphoma
[1]
[6]
[1]
[2]
[10]
[2]
Psoriasis
[12]
[38]
[6]
[2]
[19]
[2]
[12]
[51](19%)
[4]
[3]
[1]
✓
Purpura
[4]
[5]
[1]
[1]
Pustules
[1]
[2]
[1]
[5]
[2]
Pyoderma gangrenosum
[1]
[1]
Rash
[6](23%)
[4](12%)
[10](<10%)
[2](5%)
[1](7–12%)
[7](15%)
[3]
[4](<10%)
[13](25%)
[11](5%)
[6](44–50%)
[12](58%)
[19](6%)
✓✓
Raynaud’s phenomenon
[2]
[1]
[3]
Rosacea
[1]
[1]
[1]
Sarcoidosis
[6]
[8]
[3]
[1]
[1]
[1]
Scabies
[5]
[1]
[1]
Scleroderma
[1]
[1]
[7]
Serum sickness
[6]
[1]
[22](<17%)
[3]
?
Sjogren’s syndrome
[4]
[1]
Skin cancer
[1]
[1]
Squamous cell carcinoma
[5]
[5]
[10]
[12]
[4]
[1]
[1]
[2]
✓
Stevens–Johnson syndrome
[2]
[1]
[1]
[1]
[4]
[5]
[9]
✓
Striae
[1]
[1](9%)
Sweet’s syndrome
[12]
[1]
[1]
Thrombocytopenic purpura
[1]
[5]
[2]
Tinea
[1]
[3]
Toxic epidermal necrolysis
[1]
[1]
[3]
[2]
[8]
[2]
[3]
[13](<10%)
✓
Toxicity
[1]
[3](6%)
[1]
[2]
[1]
[1]
[2](75%)
[6](10%)
[2](12%)
✓
Tumors
[1]
[8](5%)
[1]
[1]
[1](11%)
Ulcerations
[1]
•
[1]
[11]
Urticaria
[1]
[3]
[5]
•
[2]
[2]
[2]
[6](17%)
[4]
[2](44–50%)
[5](8%)
[10](<5%)
✓
Vasculitis
[2]
[8](13%)
[5]
•
[3]
[21](25%)
•
[1]
[16](63%)
[9]
[7]
[3]
[4]
✓✓
Vesiculation
[1]
[1]
[1]
Vitiligo
[2]
[1]
[4]
Xerosis
[1]
[1]
[1]
HAIR
Alopecia
[3]
[9](54%)
[1]
[2]
[4](20%)
[1]
[4]
[25](10%)
[3]
[1]
[6]
✓
Alopecia areata
[7]
[6]
[1]
[1]
[3]
Follicular mucinosis
[1]
[1]
Hair pigmentation
[7](<10%)
[1]
Hirsutism
[10]
[2]
NAILS
Discoloration
[1]
[1]
•
Leukonychia (Mees’ lines)
[2]
[1]
[1]
Nail pigmentation
[3]
[2]
[4]
Onychocryptosis
[1]
[1]
[1]
Onycholysis
[1]
[1]
Onychomycosis
[2](5%)
[1](33%)
[1]
?
Pyogenic granuloma
[1]
[1]
MUCOSAL
Aphthous stomatitis
•
•
[2](9%)
[2]
[2]
[1]
Cheilitis
[1](10%)
[1]
[1]
Gingival hyperplasia/hypertrophy
[156](86%)
[1]
?
Gingivitis
•
[1](7%)
•
[1]
Glossitis
[1]
•
[1]
Mucocutaneous reactions
[1]
[2]
[1]
[2]
[2](6%)
Mucosal ulceration
[1]
[1]
Oral candidiasis
[1]
[1](11%)
[1]
Oral mucositis
[1]
[1]
[6]
Oral ulceration
[2]
[2]
[1]
[10](61%)
[5]
[3]
?
Oropharyngeal pain
[1](9%)
[1]
Stomatitis
[3](24%)
[1]
(5–7%)
[2]
[17](43%)
[6]
[2](69%)
[1](<10%)
✓
Ab Abatacept; Ad Adalimumab; Az Azathioprine; Ce Certolizumab; Cy Cyclosporine; E Etanercept; G Golimumab; H Hydroxychloroquine; I Infliximab; M Methotrexate; P Penicillamine; R Rituximab; S Sulfasalazine DPP-4 InhibitorsAlog
Lina
Saxa
Sita
=
SKIN
Anaphylaxis
[1]
[1]
✓
Angioedema
[1]
[1]
[3]
✓
Edema
[1]
[3]
✓
Exfoliative dermatitis
•
•
✓
Hypersensitivity
[2]
[1]
[1]
✓
Peripheral edema
[1]
[1](10%)
•
✓
Pruritus
[2]
[1]
[1]
✓
Rash
[1]
[1]
[1]
✓
Stevens–Johnson syndrome
[1]
[1]
✓
Urticaria
[1]
•
•
✓
Alog Alogliptin; Lina Linagliptin; Saxa Saxagliptin; Sita Sitagliptin Egfr InhibitorsC
E
G
L
Nec
Nil
P
Sor
Sun
=
SKIN
Acneform eruption
[60](92%)
[26](73–80%)
[32](66–85%)
[8](90%)
[1](23–43%)
[1](<10%)
[17](81%)
[5](<10%)
[1](<10%)
✓✓
AGEP
[1]
[1]
[2]
Anaphylaxis
[5](13%)
[1]
[1]
Angioedema
[1]
[1]
Bullous dermatitis
[1]
[1](7%)
Dermatitis
[4](80%)
[2](14%)
(<10%)
?
Desquamation
[3](89%)
[2](39%)
[3](13%)
[9](50%)
?
DRESS syndrome
[2]
[1]
Eczema
[1]
[1]
[1]
(<10%)
[2]
[1]
✓
Edema
[1]
[2](29%)
[2]
[1](15%)
[3](11%)
[6](32%)
✓
Erythema
[3](14%)
(18%)
[1]
[2]
[2](<10%)
[5](65%)
[4](19%)
[5](7%)
✓
Erythema multiforme
[1]
[10](17%)
Exanthems
[5]
[3](8%)
[3](21%)
[2]
[1]
[3]
✓
Exfoliative dermatitis
[1]
[2](14%)
[1]
[2](25%)
[1](<10%)
[1](10%)
✓
Facial edema
[1]
•
[1]
[2]
Fissures
[4](14%)
[1]
[1](22%)
[4](21%)
?
Folliculitis
[12](83%)
[9](11%)
[4]
[2]
(<10%)
[3]
[3]
✓
Hand–foot syndrome
[5](6%)
[3](30–60%)
[2]
[16](76%)
[3](23%)
[97](89%)
[61](45–65%)
✓
Hematoma
[1]
(<10%)
Hypersensitivity
[8]
[1]
[2]
Jaundice
[2](35%)
•
[1]
?
Keratosis pilaris
[1]
[1]
[1]
Necrosis
[1]
[1]
Nevi
[1]
[2]
[2]
Papulopustular eruption
[6](83%)
[7](29%)
[3](21%)
[4](21–41%)
?
Peripheral edema
[1](40%)
•
[1](44%)
[1](12%)
[1](17%)
✓
Pigmentation
[1]
[2](18%)
[1]
[2]
[12](38%)
✓
Pruritus
[9](40%)
[8](21%)
[4](61%)
[6](33%)
[2](60%)
[8](9–21%)
[9](91%)
[10](21%)
[3](<10%)
✓✓
Psoriasis
[1]
[2]
[1]
[2]
Purpura
[3]
[1]
Pustules
[1]
[1]
[1]
Pyoderma gangrenosum
[1]
[4]
Radiation recall dermatitis
[1]
[1]
[3]
[1]
Rash
[46](89%)
[105](80%)
[59](66–85%)
[48](55%)
[7](53%)
[10](56%)
[28](91%)
[46](30–75%)
[47](14–38%)
✓✓
Rosacea
[1]
[2]
[1]
Seborrheic dermatitis
[1]
[1]
[1]
Skin reactions
[1]
[1]
Squamous cell carcinoma
[1]
[1]
[7]
Stevens–Johnson syndrome
[1]
[1]
Telangiectasia
[1]
[1]
[1]
Toxic epidermal necrolysis
[2]
[1]
Toxicity
[18](63%)
[7](84%)
[9](68%)
[12](46%)
[1](8%)
[6]
[25](95%)
[14](75%)
[20](67%)
✓✓
Ulcerations
[1]
[2]
[1]
Urticaria
[1]
(<10%)
•
Vasculitis
[1]
[1]
[1]
Xerosis
[14](49%)
[11](56%)
[11](53%)
[2](29%)
[2](67%)
[12](62%)
[6](14%)
[3](17%)
✓
HAIR
Alopecia
(5%)
[10](14%)
[6]
[4](33%)
[2](<10%)
[3](54%)
[24](67%)
[3](5–12%)
✓
Hair changes
[3]
[3]
[2](9%)
Hair pigmentation
[1]
[7](38%)
?
Hypertrichosis
[3]
[4]
[2]
NAILS
Nail changes
[1](21%)
[2](17%)
[1](17%)
[2](9–29%)
?
Nail disorder
[2]
[2](10%)
[1](<10%)
Paronychia
[14](14%)
[11](15%)
[13](14–32%)
[6](27%)
[12](85%)
✓
Pyogenic granuloma
[1]
[1]
[2]
[1]
Splinter hemorrhage
[3](70%)
[1]
?
Subungual hemorrhage
[1]
[3]
MUCOSAL
Aphthous stomatitis
[1]
[1]
[1]
Cheilitis
[2](14%)
[1]
Epistaxis
[1]
[1]
[2](11%)
[2](13%)
Glossodynia
(<10%)
[1](15%)
Mucosal inflammation
[1](18%)
[2](15%)
(6%)
[4](54%)
?
Mucositis
[10]
[9](21%)
[4](6–17%)
[4](11–35%)
[4](75%)
[12](28%)
[16](~60%)
✓
Oral mucositis
[1](33%)
(6%)
[1](20%)
?
Oral ulceration
[1]
[1]
[1]
•
[1](5%)
✓
Oropharyngeal pain
•
[1](10%)
Stomatitis
[3](25%)
[9](9–19%)
[7](6–17%)
[2](41%)
(11%)
•
[4](100%)
[11](28%)
[15](60%)
✓
Xerostomia
(11%)
[1](11%)
[1](<10%)
[2](~60%)
?
C Cetuximab; E Erlotinib; G Gefitinib; L Lapatinib; Nec Necitumumab; Nil Nilotinib; P Panitumumab; Sor Sorafenib; Sun Sunitinib FluoroquinolonesB
C
L
M
N
=
SKIN
AGEP
[3]
[1]
[1]
✓
Anaphylaxis
[15]
[5]
[5]
•
✓
Bullous dermatitis
[1]
[2]
[1]
✓
Candidiasis
[2]
•
•
✓
Diaphoresis
[4]
•
•
•
✓
Edema
•
•
Erythema
[2]
•
Erythema multiforme
[5]
[1]
Erythema nodosum
[1]
•
Exanthems
[4]
[2]
•
[2]
✓
Fixed eruption
[12]
[2]
Hypersensitivity
[1]
[5]
[5]
[6]
✓
Photosensitivity
[18]
[3]
[5]
[1]
✓
Phototoxicity
[5]
[5]
[4]
✓
Pigmentation
•
[1]
Pruritus
[10]
[2]
[2]
[1]
✓
Purpura
[4]
[2]
Radiation recall dermatitis
[1]
[2]
Rash
[12](<10%)
[1]
[3]
•
✓
Stevens–Johnson syndrome
[8]
[2]
[1]
✓
Sweet’s syndrome
[1]
[1]
Thrombocytopenic purpura
[1]
[2]
Toxic epidermal necrolysis
[10]
[5]
[2]
[2]
✓
Toxicity
[2]
[1]
Urticaria
[8]
[3]
[1]
✓
Vasculitis
[11]
[3]
MUCOSAL
Stomatitis
[3]
[1]
Xerostomia
[3]
•
[1]
•
✓
B Besifloxacin; C Ciprofloxacin; L Levofloxacin; M Moxifloxacin; N Norfloxacin Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)A
C
D
E
F
Ib
In
Ktp
Ktl
Mx
Np
O
P
Su
=
SKIN
AGEP
[2]
[7]
[1]
[5](50%)
[1]
[1]
?
Anaphylaxis
[16](<10%)
[8]
[16](48%)
[1]
[5](25%)
•
[4]
[3]
[1]
[2]
•
•
[4]
✓
Angioedema
[64](22%)
[9]
[2]
[1]
[1]
[8]
[2]
[1]
[1]
[3]
[5]
•
[3]
•
✓✓
Bullous dermatitis
[8]
[1]
[2]
[3]
[2]
[1](29%)
•
[5]
[1]
✓
Bullous pemphigoid
[2]
[1]
[1]
[2]
Churg-Strauss syndrome
[2]
[1]
Dermatitis
[2]
[9]
[1]
[5]
[5]
[29]
(3–9%)
[5]
[1]
✓
Dermatitis herpetiformis
[2]
[2]
[1]
[1]
[2]
Dermatomyositis
[2]
[1]
Diaphoresis
•
•
[1]
•
[1]
[2](<10%)
[3]
•
[1]
✓
DRESS syndrome
[2]
[1]
[1]
[4]
[4]
[1]
Ecchymoses
[1]
•
•
[1]
(3–9%)
•
•
•
✓
Eczema
•
(3–9%)
[1]
[1]
[3]
[1]
Edema
[5](6%)
(3–9%)
[1]
[1](3–9%)
(<10%)
[1](6%)
[1](<9%)
•
•
✓
Embolia cutis medicamentosa (Nicolau syndrome)
[16]
[2]
[1]
[1]
Erythema
[2](14%)
[4]
[3](21%)
[1]
[2]
[1]
[1]
[1]
✓
Erythema multiforme
[18]
[3]
[6]
•
•
[11](13%)
[1]
[1]
[1]
[2]
[1]
[12]
[8]
✓
Erythema nodosum
[18]
•
[1](<5%)
[1]
[1]
Erythroderma
[4]
[2]
Exanthems
[22](18%)
[7](49%)
[6](<5%)
[2]
[3]
[9]
[7](11%)
[3]
[1](3–9%)
[1]
[9](14%)
[1]
[8]
[9](<5%)
✓✓
Excoriations
[1](6%)
[1]
Exfoliative dermatitis
[2]
[1]
[1]
•
[1]
[1]
•
•
•
[1]
•
✓
Facial edema
[1]
[1]
[2]
•
[1]
Fixed eruption
[42]
[2]
[4](18%)
[2]
[2]
[14]
[2]
[1]
[24](24%)
[15]
[5]
✓
Hematoma
[2]
[2]
[3]
Herpes simplex
[2]
•
[1]
Herpes zoster
•
[1]
Hot flashes
•
•
•
•
•
•
[1]
•
•
✓
Hypersensitivity
[10]
[8]
[4]
[4]
[5]
•
[2]
[2](5%)
[2]
•
✓
Jaundice
[1]
[1]
•
[1]
Lichen planus
[1]
[3]
[1]
Lichenoid eruption
[4]
[3]
[5]
Linear IgA
[6]
[1]
[1]
[1]
[3]
Lupus erythematosus
[1]
[5]
[2]
[1]
Pemphigus
[2]
[1]
[1]
[1]
[3]
Peripheral edema
[2]
[2]
[1]
[1]
[2](5%)
•
[1]
[1]
[1]
✓
Petechiae
•
•
Photoallergic reaction
[1]
[1]
[2]
Photosensitivity
•
[4]
[1]
•
[6]
[1]
[34](11%)
•
•
[16]
•
[40]
[2]
✓
Phototoxicity
[1]
[1]
•
Pityriasis rosea
[6]
[1]
Pruritus
[12]
[6]
[6](<10%)
[7](<10%)
[1](<5%)
[5](<5%)
[3](<10%)
[4](<10%)
[1](<10%)
[3]
[5](17%)
(<10%)
[6](<10%)
[5](<10%)
✓✓
Pseudolymphoma
[2]
[1]
[1]
[1]
[1]
[1]
[1]
[1]
✓
Psoriasis
[6]
[1]
[2]
[7]
[1]
[1]
Purpura
[16]
[1]
[2]
[1]
[5]
[1]
[1](<10%)
•
[4]
[2]
[2]
✓
Purpura fulminans
[2]
[1]
Pustules
[1]
[2]
Rash
(<10%)
[11](40%)
[4](6%)
[5]
•
[2]
[1]
[1]
[1](<10%)
[3]
[2](3–9%)
[2]
[1]
•
✓✓
SDRIFE
[2]
[1]
[1]
Serum sickness
[1]
[1]
•
•
[1]
Stevens–Johnson syndrome
[12]
[2]
[5]
•
•
[10](17%)
•
•
•
[1]
[1]
[2]
[2]
[5]
✓✓
Toxic epidermal necrolysis
[18]
[5]
[4]
•
[1]
[8](6%)
[6]
[1]
•
[1]
[5]
[4]
[12]
[13]
✓✓
Urticaria
[144](83%)
[11]
[7]
•
•
[10]
[7]
[6]
[1]
[4]
[6](<5%)
•
[7]
[4]
✓✓
Vasculitis
[4]
[4]
[3]
[2]
[1]
[8]
[5]
[1]
•
[9]
[3]
•
✓
Vesiculobullous eruption
[2]
[1]
Wound complications
[1]
[1]
Xerosis
•
[3]
[1]
[1]
HAIR
Alopecia
[2]
[3]
•
•
[2]
•
[1]
•
•
[3]
[3]
•
✓
NAILS
Nail changes
•
•
[1]
Onycholysis
[1]
[1]
MUCOSAL
Aphthous stomatitis
[6]
[1]
[1]
[1]
[4]
Epistaxis
[2]
•
•
•
[1]
Glossitis
•
•
Oral lesions
[1]
[2](7%)
[1]
Oral lichenoid eruption
[2]
[1]
[1]
[1]
Oral mucosal eruption
[6]
[2]
Oral mucosal fixed eruption
[1]
[1]
Oral ulceration
[8]
[1]
[1]
[4]
[1]
[1]
Rectal hemorrhage
•
[1]
Rectal mucosal ulceration
[2]
[1]
Stomatitis
[4](8%)
•
•
(<10%)
•
•
•
[2]
✓
Tongue edema
[1]
[1]
•
Ulcerative stomatitis
[1]
•
Xerostomia
•
[2](26%)
•
•
[1]
[2]
•
[2]
•
[2]
✓
A Aspirin; C Celecoxib; D Diclofenac; E Etodolac; F Flurbiprofen; Ib Ibuprofen; In Indomethacin; Ktp Ketoprofen; Ktl Ketorolac; Mx Meloxicam; Np Naproxen; O Oxaprozin; P Piroxicam; Su Sulindac Proton Pump Inhibitors (PPI)D
E
L
O
P
R
=
SKIN
Acneform eruption
•
•
•
•
✓
AGEP
[1]
[2]
Anaphylaxis
•
[1]
[6]
[7]
[7]
✓
Angioedema
•
[5]
•
✓
Candidiasis
•
•
Dermatitis
•
•
[1]
[1]
•
✓
Diaphoresis
•
[1]
[1]
[1]
•
✓
Ecchymoses
•
•
Eczema
[1]
•
Edema
•
[1]
[2](<10%)
•
✓
Erythema multiforme
[2]
[1]
•
✓
Erythroderma
[1]
[2]
Exanthems
•
[1]
•
✓
Exfoliative dermatitis
[1]
[1]
[3]
✓
Facial edema
[2]
[1]
[1]
•
✓
Fixed eruption
[2]
[1]
Fungal dermatitis
•
•
Herpes zoster
•
•
•
✓
Hypersensitivity
[3]
[2]
[1]
[1]
✓
Lichenoid eruption
[1]
[2]
[1]
✓
Lupus erythematosus
[2]
[3]
[5]
[3]
✓
Peripheral edema
•
[2]
[2]
[2]
•
✓
Photosensitivity
[1]
[1]
•
✓
Pigmentation
[1]
•
Pruritus
•
•
[1](3–10%)
[8](<10%)
[1]
[2]
✓✓
Pruritus ani et vulvae
•
[1]
Psoriasis
[1]
•
Rash
•
[1]
(3–10%)
[6]
[2]
[2]
✓✓
Stevens–Johnson syndrome
[1]
•
•
✓
Sweet’s syndrome
[1]
[1]
Toxic epidermal necrolysis
[4]
[5]
•
✓
Urticaria
•
•
[3]
[8](<10%)
[2]
•
✓✓
Vasculitis
[2]
[1]
Xerosis
[1]
[2]
•
•
✓
HAIR
Alopecia
•
[2]
•
•
✓
MUCOSAL
Gingivitis
•
•
Glossitis
[1]
•
•
✓
Oral candidiasis
•
[3]
•
✓
Stomatitis
[2]
[1]
•
•
✓
Tongue edema
•
[1]
Xerostomia
•
•
•
[2](<10%)
•
•
✓✓
D Dexlansoprazole; E Esomeprazole; L Lansoprazole; O Omeprazole; P Pantoprazole; R Rabeprazole StatinsA
F
L
Pi
Pr
R
S
=
SKIN
Acneform eruption
•
[1](36%)
?
Dermatomyositis
[3]
[1]
[1]
[2]
[5]
✓
Diaphoresis
•
[1]
Ecchymoses
•
•
Eczema
•
[1]
[4](5%)
Edema
•
[1](6%)
•
[1]
✓
Eosinophilic fasciitis
[1]
[2]
Erythema multiforme
[1]
[2]
Exanthems
[3](5%)
[1]
Herpes zoster
[1]
[1]
[1]
[1]
[1]
[1]
✓
Hypersensitivity
[1]
•
[1]
Jaundice
[2]
[1]
Lichenoid eruption
[1]
[1]
[1]
[2]
[1]
✓
Lupus erythematosus
[2]
[2]
[4]
[1]
[5]
✓
Peripheral edema
•
[2](50%)
?
Petechiae
•
[1]
Photosensitivity
•
[1]
[7]
Pruritus
[1]
[2](5%)
[2]
•
[3]
✓
Purpura
[1]
[1]
[3]
Radiation recall dermatitis
[1]
[1]
Rash
[2]
•
[3](5%)
•
[7](5–7%)
•
[3](<10%)
✓✓
Toxicity
[2]
[1]
[1]
✓
Urticaria
[1]
•
[1]
Vasculitis
[1]
[2]
HAIR
Alopecia
[1]
•
MUCOSAL
Cheilitis
•
[1]
Stomatitis
•
[1](64%)
?
A Atorvastatin; F Fluvastatin; L Lovastatin; Pi Pitavastatin; Pr Pravastatin; R Rosuvastatin; S Simvastatin Tnf InhibitorsA
C
E
G
I
=
SKIN
Abscess
[1]
[2]
[4]
✓
Acneform eruption
[2]
[1]
[6]
✓
AGEP
[1]
[2]
Anaphylaxis
[1]
[2]
[10]
✓
Angioedema
[3]
•
[1]
[1]
✓
Basal cell carcinoma
[1]
[1]
Bullous pemphigoid
[1]
[1]
Candidiasis
[1]
[4](5%)
Carcinoma
[2]
[2]
Cellulitis
[2](<5%)
[2]
[5]
✓
Dermatitis
[1]
•
[3]
[4]
✓
Dermatomyositis
[5]
[4]
Eczema
[2]
[5](19–30%)
?
Erythema
[1]
[1]
Erythema multiforme
[1]
[2]
Erythema nodosum
[1]
[1]
Exanthems
[2]
[4]
Fixed eruption
[1]
[1]
[1]
✓
Folliculitis
[1]
[2]
Granuloma annulare
[1]
[1]
Granulomas
[1]
[2]
[1]
✓
Granulomatous reaction
[5]
[5]
[1]
✓
Henoch–Schönlein purpura
[2]
[3]
[1]
✓
Herpes simplex
[1]
[1]
[4](10%)
✓
Herpes zoster
[9]
[2]
[5]
[10]
✓
Hidradenitis
[2]
[2]
[1]
✓
Hypersensitivity
[3]
•
[1]
[11](11%)
✓
Kaposi’s sarcoma
[1]
[1]
Leprosy
[1]
[2]
[1]
✓
Leukocytoclastic vasculitis
[1]
[1]
[1]
✓
Lichen planus
[2]
[2]
Lichenoid eruption
[5]
[3]
[3]
✓
Lupus erythematosus
[16]
[25]
[3]
[33]
✓
Lupus syndrome
[3]
[2]
[2]
[11]
✓
Lymphadenopathy
[1]
[1]
Lymphoma
[8]
[3]
[9]
✓
Lymphoproliferative disease
[1]
[1]
Malignancies
[3]
[3]
[5]
[2]
✓
Melanoma
[6]
[2]
[1]
[1]
✓
Molluscum contagiosum
[1]
[2]
Morphea
[1]
[1]
Necrotizing fasciitis
[1]
[1]
Neoplasms
[1]
[2]
[2]
[2]
✓
Nevi
[1]
[2]
Peripheral edema
(<5%)
[1]
[1]
✓
Pityriasis lichenoides chronica
[1]
[1]
[2]
✓
Pruritus
[5]
[1]
[2](14%)
[8](20%)
✓
Pseudolymphoma
[1]
[1]
[2]
✓
Psoriasis
[38]
[6]
[19]
[2]
[51](19%)
✓✓
Pustules
[1]
[2]
[5]
✓
Rash
[4](12%)
[2](5%)
[7](15%)
[3]
[13](25%)
✓✓
Rosacea
[1]
[1]
[1]
✓
Sarcoidosis
[6]
[8]
[3]
✓
Serum sickness
•
[6]
Skin cancer
[1]
[1]
Squamous cell carcinoma
[5]
[4]
[1]
[1]
✓
Stevens–Johnson syndrome
[2]
•
[1]
✓
Toxicity
[1]
[1]
[1]
[2](75%)
✓
Tumors
[1]
[1]
Urticaria
[3]
•
[2]
[6](17%)
✓
Vasculitis
[8](13%)
•
[21](25%)
•
[16](63%)
✓✓
Vitiligo
[2]
[4]
HAIR
Alopecia
[3]
[1]
[4](20%)
[4]
✓
Alopecia areata
[7]
[1]
[1]
[3]
✓
Follicular mucinosis
[1]
[1]
A Adalimumab; C Certolizumab; E Etanercept; G Golimumab; I Infliximab Tyrosine-Kinase InhibitorsAft
Axt
Cbo
Crz
Dsa
Erl
Gft
Imt
Lpt
Lnv
Nlo
Nnt
Srf
Snt
Vnd
=
SKIN
Acneform eruption
[24](92%)
[1](<10%)
[26](73–80%)
[32](66–85%)
[2]
[4](90%)
[1](<10%)
[5](<10%)
[1](<10%)
[3](35%)
✓
AGEP
[1]
[1]
[6]
[2]
Bullous dermatitis
•
[1]
[1](7%)
Dermatitis
[1](21%)
(<10%)
[2](14%)
(<10%)
[1]
?
Desquamation
[2](39%)
[9](50%)
?
Diaphoresis
(13%)
[1](6%)
DRESS syndrome
[2]
[3]
[1]
Eczema
(<10%)
[1]
[1]
(<10%)
[1]
Edema
[9](38%)
[5](23%)
[1]
[33](80%)
[1](29%)
[2]
[3](11%)
[6](32%)
✓
Erythema
[1]
(11%)
[1]
(18%)
[1]
[5](<10%)
[1]
[2](<10%)
[4](19%)
[5](7%)
✓
Erythema multiforme
[1]
[1]
[1]
[10](17%)
[1]
Exanthems
[3](8%)
[3](21%)
[8]
[1]
(21%)
[1]
[3]
✓
Exfoliative dermatitis
•
[1]
[3]
[1](14%)
[1]
[1](<10%)
[1](10%)
✓
Facial edema
[1]
[2](<10%)
•
[1]
[2]
Fissures
[2](12%)
[1]
Folliculitis
[1]
[9](11%)
[4]
[1]
(<10%)
[3]
[4](49%)
✓
Hand–foot syndrome
[2](10%)
[15](64%)
[14](50%)
[3](30–60%)
[2]
[3]
[8](76%)
(32%)
[2]
[97](89%)
[61](45–65%)
[3](36%)
✓
Herpes
(<10%)
•
Hyperhidrosis
(<10%)
[1]
(<10%)
[1](12%)
Hyperkeratosis
(7%)
(7%)
[4]
Hypersensitivity
•
[2]
Hypomelanosis
[5]
[1]
Jaundice
(25%)
[1](35%)
•
[1]
?
Keratosis pilaris
[1]
[1]
[1]
Lesions
[1]
[2](38%)
?
Necrolysis
[1]
[1]
Necrosis
[1]
[1]
Nevi
[1]
[2]
[2]
Palmar–plantar hyperkeratosis
[1]
[1]
Panniculitis
[3]
[2]
Papulopustular eruption
[7](29%)
[3](21%)
[1]
?
Peripheral edema
[5](28%)
[3](44%)
•
[5](75%)
[2](37%)
[1](44%)
[1](17%)
✓
Photosensitivity
[2]
•
[1]
[1](<10%)
[6](23%)
?
Phototoxicity
[1]
[2]
Pigmentation
•
[1]
[9](60%)
[1](18%)
[2]
[12](38%)
[4]
✓
Pityriasis rubra pilaris
[1]
[1]
Pruritus
[2](13%)
[1](8%)
[3](14%)
[8](21%)
[4](61%)
[3](10%)
[3](33%)
[8](9–21%)
[1](19%)
[10](21%)
[3](<10%)
[2](11%)
✓
Psoriasis
[2]
[1]
[1]
[2]
Purpura
[3]
[1]
[1]
Pyoderma gangrenosum
[1]
[4]
Radiation recall dermatitis
[1]
[3]
[1]
Rash
[43](92%)
[3](14%)
[1](30%)
[4](16%)
[9](34%)
[105](80%)
[59](66–85%)
[23](69%)
[24](55%)
(21%)
[10](56%)
[4](41%)
[47](30–75%)
[14](14–38%)
[32](67%)
✓✓
Rosacea
[2]
[1]
[1]
Seborrheic dermatitis
[1]
[1]
[1]
Skin reactions
[1]
[1]
Squamous cell carcinoma
[1]
[2]
[1]
[7]
Stevens–Johnson syndrome
[1]
[11]
[1]
[2]
Sweet’s syndrome
•
[1]
[1]
Telangiectasia
[1]
[1]
Toxic epidermal necrolysis
[1]
[1]
Toxicity
[2]
[2]
[6](36%)
[7](84%)
[9](68%)
[8](30–44%)
[6](46%)
[1]
[6]
[14](75%)
[20](67%)
[9](48–50%)
✓
Ulcerations
•
[2]
[1]
Urticaria
(<10%)
[1]
[1]
(<10%)
•
Vasculitis
[1]
[1]
[1]
[1]
Wound complications
[1]
[1]
[1]
Xerosis
[6](15%)
(10%)
[1](23%)
(<10%)
[11](56%)
[11](53%)
[1](<10%)
[1](29%)
[1](20%)
[6](14%)
[3](17%)
[2](15%)
✓
HAIR
Alopecia
[1](7%)
[2](6%)
(16%)
[1](<10%)
[10](14%)
[6]
[1](10–15%)
[2](33%)
(12%)
[2](<10%)
[2](71%)
[24](67%)
[3](5–12%)
[1]
✓
Hair changes
(34%)
[3]
[1]
?
Hair pigmentation
[2](34%)
[2]
[1]
[7](38%)
?
Hypertrichosis
[4]
[2]
NAILS
Nail changes
[2](16%)
[2](17%)
[1](17%)
Nail disorder
•
[1](10%)
[1](<10%)
Nail pigmentation
[1]
[1]
Paronychia
[9](33–85%)
[11](15%)
[13](14–32%)
[3](27%)
[3](7%)
?
Pyogenic granuloma
[1]
[2]
Splinter hemorrhage
[3](70%)
[1]
[1]
?
Subungual hemorrhage
[1]
[3]
MUCOSAL
Aphthous stomatitis
•
[1]
[1]
(41%)
[1]
?
Cheilitis
[1](7%)
[1]
[1](14%)
[1]
Epistaxis
[3](17%)
[1](8%)
[1]
(12%)
[1]
[2](11%)
[2](13%)
✓
Glossodynia
[1]
(25%)
(<10%)
[1](15%)
?
Mucocutaneous eruption
[1]
[1]
[1]
Mucosal inflammation
[6](69%)
[2](15%)
[2](23%)
[1](18%)
[1](15%)
[1](50%)
[4](54%)
[1](27%)
✓
Mucositis
[10](50–90%)
[1]
[1](16%)
[9](21%)
[4](6–17%)
[2](15%)
[2](11–35%)
[12](28%)
[16](~60%)
[2](14%)
✓
Oral mucositis
[1]
[1](33%)
[1](20%)
?
Oral ulceration
[1]
[1]
[3](15%)
(41%)
•
[1](5%)
?
Oropharyngeal pain
[1]
(25%)
[1](10%)
?
Rhinorrhea
(11%)
•
Stomatitis
[17](50–90%)
[1](15%)
(51%)
[1](11%)
[1]
[9](9–19%)
[7](6–17%)
[1](41%)
[2](41%)
•
[1]
[11](28%)
[15](60%)
[2](33%)
✓
Xerostomia
[1](20%)
[1](33%)
[1](44%)
(17%)
[1](11%)
[1](<10%)
[2](~60%)
✓
Aft Afatinib; Axt Axitinib; Cbo Cabozantinib; Crz Crizotinib; Dsa Dasatinib; Erl Erlotinib; Gft Gefitinib; Imt Imatinib; Lpt Lapatinib; Lnv Lenvatinib; Nlo Nilotinib; Nnt Nintedanib; Srf Sorafenib; Snt Sunitinib; Vnd Vandetanib 316 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362